专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明授权

EP2854980B1 SELECTIVE BINDING OF BIOLOGICAL TARGETS TO SOLID PHASE UREIDES 有权
标题翻译：生物靶向固相尿素的选择性结合
公开(公告)号：EP2854980B1
公开(公告)日：2017-11-01
申请号：EP13798068.6
申请日：2013-05-30
申请人： Agency for Science, Technology and Research
发明人： GAGNON, Peter
IPC分类号： B01D15/26 , B01D15/38 , B01J20/286 , B01J20/32 , C07K1/22 , C07K14/77
CPC分类号： C12N7/00 , B01D15/265 , B01D15/3804 , B01J20/286 , B01J20/3251 , C07H1/08 , C07K1/22 , C07K1/36 , C07K14/77 , C07K16/00 , C12N5/0602 , C12N2770/24151 , C12N2795/00051
摘要： A method of selectively separating a biological target from a sample including the biological target material or suspected of including the biological target includes the steps of (i) providing a solid including ureide moieties at its surface, (ii) contacting the sample with the solid, whereby a substantial fraction of the biological target in the sample binds to the ureide moieties, and (iii) separating the solid from the sample.

3. 发明授权

EP1721987B1 Methods for treating cancers and pathogen infections using dendritic cells loaded with RNA 失效
标题翻译：用于治疗癌症和使用树突细胞致病性感染装载有RNA的治疗方法
公开(公告)号：EP1721987B1
公开(公告)日：2015-11-11
申请号：EP06015438.2
申请日：1997-04-30
申请人： Duke University
发明人： Nair, Smita K. , Boczkowski, David J. , Gilboa, Eli
IPC分类号： C12N15/87 , A61K39/00 , A61K39/12 , C07K14/47 , A61P35/00 , A61P31/12
CPC分类号： C12N15/625 , A61K39/0011 , A61K2039/5154 , A61K2039/53 , C07K14/4748 , C07K14/705 , C07K14/77 , C07K2319/035 , C07K2319/036 , C07K2319/75 , C12N5/0634 , C12N15/87 , C12N2510/00 , G01N33/505 , Y02A50/466
摘要： The invention relates to antigen presenting cells (APCs) that present on their surface a tumor or pathogen antigenic epitope encoded by tumor or pathogen derived RNA, wherein the epitope induces T cell proliferation, wherein said APCs are produced by a method comprising: (i) introducing into a antigen-presenting cell in vitro tumor-derived RNA comprising tumor-specific RNA that encodes an antigen that induces T cell proliferation and tumor immunity; or (ii) introducing into a antigen-presenting cell in vitro pathogen-derived RNA consisting essentially of RNA encoding a pathogen antigen that induces T cell proliferation and an immune response to the pathogen and thereby producing an APC that presents on its surface a tumor or pathogen antigenic epitope encoded by the RNA, wherein the epitope induces T cell proliferation.

4. 发明公开

EP2753360A1 NANOPARTICLE-PEPTIDE COMPOSITIONS 有权转让
标题翻译：纳米肽组合物
公开(公告)号：EP2753360A1
公开(公告)日：2014-07-16
申请号：EP12756725.3
申请日：2012-09-07
申请人： Midatech Ltd.
发明人： RADEMACHER, Thomas , WILLIAMS, Phillip
IPC分类号： A61K47/48 , A61P35/00 , A61P31/00
CPC分类号： C07K14/4748 , A61K38/38 , A61K39/0011 , A61K47/6923 , A61K47/6929 , A61K2039/55516 , A61K2039/572 , A61K2039/60 , A61K2039/627 , C07K7/06 , C07K7/08 , C07K14/77
摘要： The present invention provides nanoparticles and compositions comprising such nanoparticles, as well as methods for intracellular delivery of peptides, and methods of producing nanoparticles and related products. The nanoparticles comprise a core comprising a metal and/or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that is covalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises a peptide of choice that is covalently linked to the core via a second linker. The second linker comprises a peptide portion and a non- peptide portion, wherein said peptide portion of said second linker comprises the sequence X
1 X
2 Z
1 , wherein: X
1 is an amino acid selected from A and G; X
2 is an amino acid selected from A and G; and Z
1 is an amino acid selected from Y and F.

5. 发明公开

EP2444408A3 METHOD OF PURIFYING/CONCENTRATING SUGAR CHAIN WITH SUGAR CHAIN-TRAPPING MOLECULE AND METHOD OF ANALYZING SUGAR CHAIN STRUCTURE 审中-公开
标题翻译：对于糖链ZUCKERKETTENEINFANGENDEM分子清洁/浓度和分析过程方法的糖链结构
公开(公告)号：EP2444408A3
公开(公告)日：2014-01-01
申请号：EP11192486.6
申请日：2003-12-25
申请人： Shionogi & Co., Ltd.
发明人： Nishimura, Shinichrio , Niikura, Kenichi , Nakagawa, Hiroaki , Okayama, Minenobu
IPC分类号： C07H1/08
CPC分类号： C07H1/08 , C07C239/20 , C07H1/06 , C07H3/06 , C07K1/14 , C07K14/77 , C07K14/79 , C07K16/00 , G01N33/5308 , G01N33/6842 , G01N2333/77 , G01N2333/79 , G01N2400/00 , G01N2560/00
摘要： The present invention provides substance which can specifically interact with sugar chains. Further, the present invention provides a method for separating, concentrating, or purifying sugar chains or a sugar chain-containing substance in a sample, comprising the steps of: a) contacting a sugar chain-trapping carrier comprising a substance which can specifically interact with sugar chains with the sample in a fluid phase under conditions that the sugar chain-trapping carrier can react with the sugar chains or sugar chain-containing substance; b) isolating a composite of the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance from the fluid phase; and c) exposing the composite to the conditions that the interaction between the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance is at least partially eliminated.
摘要翻译：本发明提供了可以与糖链特异性地发生相互作用的物质。此外，本发明提供了用于分离，浓缩或纯化的糖链或样品中的含糖链物质的方法，包括以下步骤的方法：a）使捕捉糖链的载体包含可以与特异性地发生相互作用的物质糖链与条件下的流体相的样品做了捕捉糖链的载体可以与糖链或含糖链物质反应; b）分离捕捉糖链的载体的从流体相的复合体与糖链或含糖链物质; 和c）暴露该复合的条件并在捕捉糖链的载体与糖链或含糖链物质之间的相互作用至少部分被消除。

6. 发明公开

EP2538221A3 Biochemical markers for CVD risk assessment 审中-公开
标题翻译：生化标志物评估心血管疾病风险
公开(公告)号：EP2538221A3
公开(公告)日：2013-04-24
申请号：EP12185050.7
申请日：2008-11-04
申请人： Nordic Bioscience A/S
发明人： Karsdal, Morten , Qvist, Per , Barascuk, Natasha
IPC分类号： G01N33/68 , C12Q1/37 , G01N33/542 , C07K14/47
CPC分类号： G01N33/6878 , C07K14/77 , C07K14/775 , C07K14/78 , C12Q1/37 , G01N33/542 , G01N33/577 , G01N33/6893 , G01N2800/32 , G01N2800/50 , G01N2800/52
摘要： A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque by a proteinase, wherein the protein is versican and said method comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

7. 发明公开

EP2538222A8 Biochemical markers for CVD risk assessment 有权转让
公开(公告)号：EP2538222A8
公开(公告)日：2013-02-27
申请号：EP12185053.1
申请日：2008-11-04
申请人： Nordic Bioscience A/S
发明人： Karsdal, Morten , Qvist, Per , Barascuk, Natasha
IPC分类号： G01N33/68 , C07K14/47 , C12Q1/37 , G01N33/542
CPC分类号： G01N33/6878 , C07K14/77 , C07K14/775 , C07K14/78 , C12Q1/37 , G01N33/542 , G01N33/577 , G01N33/6893 , G01N2800/32 , G01N2800/50 , G01N2800/52
摘要： A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque by a proteinase, wherein the protein is CRP and said method comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

8. 发明公开

EP1913954A4 AGENTS AND METHODS BASED ON THE USE OF THE EDA DOMAIN OF FIBRONECTIN 失效转让
标题翻译： AGENT AND METHOD FOR纤连蛋白的EDA领域的用途
公开(公告)号：EP1913954A4
公开(公告)日：2011-01-12
申请号：EP06794018
申请日：2006-06-13
申请人： PROYECTO BIOMEDICINA CIMA SL
发明人： LECLERC CLAUDE , LASARTE SAGASTIBELZA JUAN JOSE , GORRAIZ AYALA MARTA , PRIETO VALTUENA JESUS
IPC分类号： A61K38/39 , A61P37/04 , C07K14/18 , C07K14/78 , C07K19/00
CPC分类号： C07K14/78 , A61K38/39 , A61K39/0011 , C07K14/77 , C07K2319/33 , C07K2319/40 , C12N2770/24211 , C12N2770/24234
摘要： This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.

9. 发明授权

EP1023442B1 TRANSGENIC BIRDS AND PROTEIN PRODUCTION 有权
标题翻译：转基因鸟类和蛋白生产
公开(公告)号：EP1023442B1
公开(公告)日：2010-11-24
申请号：EP98954994.4
申请日：1998-10-15
申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. , Synageva BioPharma Corp.
发明人： IVARIE, Robert, D. , HARVEY, Alex, J. , MORRIS, Julie, A. , LIU, Guodong , Rapp, Jeffrey C.
IPC分类号： C12N15/00 , A01K67/027 , C12N15/90
CPC分类号： C12N9/00 , A01K67/0275 , A01K2217/05 , A01K2217/072 , A01K2227/30 , A01K2267/01 , A01K2267/025 , C07K14/77 , C07K16/00 , C12N15/8509 , C12N15/86 , C12N15/902 , C12N2740/11043 , C12N2799/027 , C12N2800/30 , C12N2800/90 , C12N2830/00 , C12N2830/008 , C12N2830/40 , C12N2830/42 , C12N2830/90 , C12N2840/20 , C12N2840/203 , C12N2840/44
摘要： This invention provides vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of a bird and for expressing said exogenous sequences to alter the phenotype of the bird or to produce desired proteins. In particular, transgenic chickens are produced which express exogenous sequences in their oviducts. Eggs which contain exogenous proteins are also produced.

10. 发明公开

EP2013224A2 METHODS FOR ISOLATION AND ANALYSIS OF SIALYLATED AND PHOSPHORYLATED PEPTIDES 审中-公开
标题翻译：方法分离和唾液酸化和磷酸化肽的分析
公开(公告)号：EP2013224A2
公开(公告)日：2009-01-14
申请号：EP07722581.1
申请日：2007-04-27
申请人： Syddansk Universitet
发明人： LARSEN, Martin Roessel
IPC分类号： C07K1/16
CPC分类号： C07K14/4732 , C07K14/473 , C07K14/77 , G01N33/57407 , G01N2400/00
摘要： Changes in sialylation of cell surface or plasma proteins are often associated with various cancers and other disease conditions. Provided are methods of detecting biomarkers of conditions associated with a change of sialylation status. Sialylated peptides are first isolated from biological and other samples by loading onto titanium dioxide (TiO2) or zirconium dioxide (ZrO2) stationary phase under acidic conditions in a solution comprising at least 20% organic phase and at least about 6.5 mM of substituted aromatic carboxylic acid, or, alternatively, at least about 11 mM short chain, non-aromatic, hydroxylated carboxylic acid. Sialic acid containing proteins can then be eluted from loaded stationary phase material by exposure to an alkaline solution having pH of 9.0 or greater, preferably at least 10.5. Sialylated peptides isolated by the methods provided can then be analysed by mass spectrometry to identify patterns of sialylation across a sialiome (the entire complement of sialic acid containing peptides in a biological sample) and/ or to identify proteins in a sample that are sialylated or that show changes in sialylation status between two or more different samples. In preferred embodiments, sialylated peptides from control and patient samples can be differentially isotopically labelled and compared in a single mass sprectrometry experiment. Also provided are specific biomarkers of bladder cancer. The methods for isolating and analysing sialylated proteins can also by applied to phosphorylated proteins.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式